<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="and less toxicity. 1 Introduction Leishmaniasis is a vector-borne complex" exact="parasitic disease" post="caused by obligate intramacrophagic protozoan parasite Leishmania. Leishmaniasis is"/>
 <result pre="the severest with approximately 500â€¯000 new cases reported annually.2 Visceral" exact="leishmaniasis" post="(VL) or kala azar, is a lethal, chronic neglected"/>
 <result pre="hydroxycinnamic acid family that shows in vitro antiviral activity against" exact="hepatitis" post="C virus at the initial stage and antileishmanial activity.16,17"/>
 <result pre="reverse transcription of human immunodeficiency virus (HIV) and Rauscher murine" exact="leukemia" post="virus (RLV).19 Proanthocyanidins, recognized as condensed tannins, are a"/>
 <result pre="findings may be helpful for designing of the treatment of" exact="leishmaniasis" post="through the use of C. fistula alone or in"/>
 <result pre="BoelaertM.; DujardinJ. C.; ChakravartyJ.Efficacy of miltefosine in the treatment of" exact="visceral leishmaniasis" post="in India after a decade of use. Clin. Infect."/>
 <result pre="DujardinJ. C.; ChakravartyJ.Efficacy of miltefosine in the treatment of visceral" exact="leishmaniasis" post="in India after a decade of use. Clin. Infect."/>
 <result pre="K.; MahajanR.; LimaM. A.; MitraG.; VermaN.; BalasegaramM.; DasP.Risk factors for" exact="visceral leishmaniasis" post="relapse in immunocompetent patients following treatment with 20 mg/kg"/>
 <result pre="MahajanR.; LimaM. A.; MitraG.; VermaN.; BalasegaramM.; DasP.Risk factors for visceral" exact="leishmaniasis" post="relapse in immunocompetent patients following treatment with 20 mg/kg"/>
</results>
